Suggestion of treatment options for patients unable to undergo hematopoietic stem cell transplantation Onureg, an acute myelogenous leukemia maintenance treatment drug, recently entered into drug price negotiations for insurance coverage.

After passing the HIRA Cancer Disease Review Committee in December of last year and the Pharmaceutical Reimbursement Evaluation Committee last month, it entered the NHIS procedure without any major changes. Considering the deadline for negotiations, the results are expected to come out in June at the latest.

Onureg was approved on March 23, 2022, for maintenance therapy in adult patients with acute myeloid leukemia who achieved CR or CRi with incomple